Impact of hormone therapy on the overall and relapse‑free survival of patients receiving treatment for ovarian cancer
Objective: To analyze the literature data on the possibility of using different variants of hormone therapy in patients who previously underwent treatment for ovarian malignancies, oncofertility and the effect of hormone therapy on the overall and relapse-free survival of patients with different morphological variants of ovarian malignancies. The review includes the data from foreign and Russian publications in PubMed on this issue over the past ten years. This was an analysis of the possibilities and contraindications to the use of hormone therapy, as well as menopausal hormone therapy in women with different morphological variants of ovarian malignancies. It was concluded that hormone therapy can be used in patients with a history of ovarian cancer, non-epithelial malignant tumors and borderline ovarian tumors.Babaeva N.А., Yureneva S.V., Aleshikova О.I., Yakushevskaya О.V., Ashrafyan L.A.
Conclusion: The correlation between the use of hormone therapy and the risk of recurrence of neoplasms in women treated for ovarian cancer has been clearly established only for granulocellular ovarian tumors and serous tumors of low malignant potential. In case of other morphological variants of ovarian malignancies, menopausal hormone therapy should be prescribed very carefully. Before making a decision on the use of hormone therapy for each patient, it is necessary to conduct a thorough examination and consult an interdisciplinary group of specialists in order to individualize the hormone therapy plan based on the assessment of the potential risks and benefits of the treatment.
Authors’ contributions: Babaeva N.А. – developing the concept of the study, search for the literature, writing the text of the article, preparing it for the publication; Yureneva S.V. – developing the design of the study, analysis of the content of the article, editing the article; Aleshikova О.I. – search for the literature, writing the text of the article, preparing it for the publication;
Yakushevskaya О.V. – developing the design of the study, editing the article; Ashrafyan L.A. – developing the concept of the study, editing the article. All the authors took part in the discussion and correction of the work. All authors approved the final version of the publication.
Conflicts of interest: The authors declare that there are no conflicts of interest.
Funding: The study was carried without sponsorship.
For citation: Babaeva N.А., Yureneva S.V., Aleshikova О.I., Yakushevskaya О.V., Ashrafyan L.A. Impact of hormone therapy on the overall and relapse-free survival of patients receiving treatment for ovarian cancer.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2023; (4): 40-48 (in Russian)
https://dx.doi.org/10.18565/aig.2022.315
Keywords
ovarian cancer
borderline ovarian tumors
germinal ovarian tumors
sex cord-stromal tumors
menopausal hormone therapy
oncological risks
overall and relapse-free survival
References
1. Minami C.A., Freedman R.A. Menopausal hormone therapy and long‑term breast cancer risk: Further Data From the Women's Health Initiative Trials. JAMA. 2020; 324(4): 347‑9. https://dx.doi.org/10.1001/jama.2020.9620.
2. Crawford S.L., Sybil L. Hormone therapy and vasomotor symptoms after the Women’s Health Initiative. Menopause. 2014; 21(5): 439‑41. https://dx.doi.org/10.1097/GME.0000000000000228.
3. Chlebowski R.T., Anderson G.L., Aragaki A.K., Manson J.E., Stefanick M.L. Pan K. et al. Association of menopausal hormone therapy with breast cancer incidence and mortality during long‑term follow‑up of the Women’s Health Initiative Randomized Clinical Trials. JAMA. 2020; 324(4): 369‑80. https://dx.doi.org/10.1001/jama.2020.9482.
4. The National Institute for Health and Care Excellence. Menopause: diagnosis and management NICE guideline [NG23] Published date: November 2015 Last updated: December 2019. Available at: https://www.nice.org.uk/guidance/ng23. Accessed 7 January 2020.
5. de Villiers T.J., Hall J.E., Pinkerton J.V., Pérez S.C., Rees M., Yang C., Pierroz D.D. et al. Revised global consensus statement on menopausal hormone therapy. Maturitas. 2016; 91: 153‑5. https://dx.doi.org/10.1016/j.maturitas.2016.06.001.
6. Armeni E., Lambrinoudaki I., Ceausu I., Depypere H., Mueck A., Pérez- López F.R. et al. Maintaining postreproductive health: a care pathway from the European Menopause and Andropause Society (EMAS). Maturitas. 2016; 89: 63‑72. https://dx.doi.org/10.1016/j.maturitas.2016.04.013.
7. Shifren J.L., Gass M.L. NAMS recommendations for clinical care of midlife women working group. The north american menopause society recommendations for clinical care of midlife women. Menopause. 2014; 121(10): 1038‑62. https://dx.doi.org/10.1097/GME.0000000000000319.
8. Cobin R.H., Goodman N.F. AACE reproductive endocrinology scientific committee. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause‑2017 update. Endocr. Pract. 2017; 23(7): 869‑80. https://dx.doi.org/10.4158/EP171828.PS.
9. Pickar J.H., Boucher M., Morgenstern D. Tissue selective estrogen complex (TSEC): a review. Menopause. 2018; 25(9): 1033‑45. https://dx.doi.org/10.1097/GME.0000000000001095.
10. Di Donato V., Schiavi M.C., Iacobelli V., D'oria O., Kontopantelis E., Simoncini T. et al. Ospemifene for the treatment of vulvar and vaginal atrophy: a meta‑analysis of randomized trials. Part II: evaluation oftolerability and safety. Maturitas. 2019; 121: 93‑100. https://dx.doi.org/10.1016/j.maturitas.2018.11.017.
11. Якушевская О.В., Бабаева Н.А., Юренева С.В., Ашрафян Л.А. Влияние менопаузальной гормональной терапии на развитие и прогрессирование рака шейки матки и эндометрия; Акушерство и гинекология. 2022; 8: 30‑5. [Yakushevskaya O.V., Babaeva N.A., Yureneva S.V., Ashrafyan L.A. Impact of menopausal hormone therapy on the development and progression of cervical and endometrial cancers. Obstetrics and Gynecology. 2022; (8): 30‑5. (in Russian)]. https://dx.doi.org/10.18565/aig.2022.8.30‑35.
12. Sung H., Ferlay J., Siegel R.L. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021; 71(3): 209‑49. https://dx.doi.org/ 10.3322/caac.21660.
13. Momenimovahed Z., Tiznobaik A., Taheri S., Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int. J. Womens Health. 2019; 11: 287‑99. https://dx.doi.org/10.2147/IJWH.S197604.
14. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M. et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 2015; 136(5): E359‑86. https://dx.doi.org/10.1002/ijc.29210.
15. Krugmann J., Schwarz C.L., Melcher B., Sterlacci W.,Ozalinskaite A., Lermann J. et al. Malignant ascites occurs most often in patients with high‑grade serous papillary ovarian cancer at initial diagnosis: a retrospective analysis of 191 women treated at Bayreuth Hospital, 2006‑2015. Arch. Gynecol. Obstet. 2019; 299(2): 515‑23. https://dx.doi.org/10.1007/s00404‑018‑4952‑9
16. Gaona-Luviano P., Medina-Gaona L.A., Magaña-Pérez K. Epidemiology of ovarian cancer. Chin. Clin. Oncol. 2020; 9(4): 47. https://dx.doi.org/10.21037/ cco‑20‑34.
17. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018; 68(6): 394‑424. https://dx.doi.org/10.3322/caac.21492.
18. Каприн А.Д., Старинский В.В., Шахзадова А.О., ред. Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена – филиал ФГБУ "НМИЦ радиологии" Минздрава России; 2021. 252с. [Kaprin A.D., Starinsky V.V., Shakhzadova A.O., eds. Malignant neoplasms in Russia in 2020 (morbidity and mortality). Moscow; 2021. 252p. (in Russian)].
19. Gotlieb W.H., Chetrit A., Menczer J., Hirsh-Yechezkel G., Lubin F. et al. Demographic and genetic characteristics of patients with borderline ovarian tumors as compared to early stage invasive ovarian cancer. Gynecol. Oncol. 2005; 97(3): 780‑3. https://dx.doi.org/10.1016/j.ygyno.2005.02.022.
20. Koshiyama M., Matsumura N., Konishi I. Recent concepts of ovarian carcinogenesis: Type I and Type II. Biomed. Res. Int. 2014; 2014: 934261. https://dx.doi.org/10.1155/2014/934261.
21. Lim D., Oliva E. Precursors and pathogenesis of ovarian carcinoma. Pathology. 2013; 45(3): 229‑42. https://dx.doi.org/10.1097/PAT.0b013e32835f2264.
22. Kurman R.J., Shih I.-M. The Dualistic model of ovarian carcinogenesis: revisited, revised and expanded. Am. J. Pathol. 2016; 186(4): 733‑47. https://dx.doi.org/10.1016/j.ajpath.2015.11.011.
23. Bowtell D.D., Böhm S., Ahmed A.A., Aspuria P.-J., Bast R.C. Jr et al. Rethinking ovarian cancer II: Reducing mortality from high‑grade serous ovarian cancer. Nat. Rev. Cancer. 2015; 15(11): 668‑79. https://dx.doi.org/10.1038/nrc4019.
24. Beral V., Gaitskell K., Hermon C., Moser K., Reeves G., Peto R.; Collaborative Group On Epidemiological Studies of Ovarian Cancer. Menopausal hormone use and ovarian cancer risk: individual participant meta‑ analysis of 52 epidemiological studies. Lancet. 2015; 385(9980): 1835‑42. https://dx.doi.org/10.1016/S0140‑6736(14)61687‑1.
25. Rodriguez C., Eugenia E. Calle E.E., Coates R.J., Miracle-McMahill H.L., Thun M.J., Heath C.W. Jr. Estrogen replacement therapy and fatal ovarian cancer. Am. J. Epidemiol. 1995; 141(9): 828‑35. https://dx.doi.org/10.1093/ oxfordjournals.aje.a117518.
26. Guidozzi F., Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: a randomised control trial. Cancer. 1999; 86(6): 1013‑8. https://dx.doi.org/10.1002/(sici)1097‑0142(19990915)86:6<1013::aid‑ cncr17>3.0.co;2‑1.
27. Eeles R.A., Morden J.P., Gore M., Mansi J., Glees J, Wenczl M. et al. Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial. J. Clin. Oncol. 2015; 33(35): 4138‑44. https://dx.doi.org/10.1200/JCO.2015.60.9719.
28. Eeles R.A., Tan S., Wiltshaw E., Fryatt I., A'Hern R.P., Shepherd J.H., Harmer C.L. et al. Hormone replacement therapy and survival after surgery for ovarian cancer. BMJ. 1991; 259‑62. https://dx.doi.org/1010.1136/bmj.302.6771.259.
29. Bebar S., Ursic-Vrscaj M. Hormone replacement therapy after epithelial ovarian cancer treatment. Eur. J. Gynecol. Oncol. 2000; 21(2): 192‑6.
30. Ursic-Vrscaj M., Bebar S., Zakelj M.P. Hormone replacement therapy after invasive ovarian cystadenocarcinoma treatment: the effect on survival. Menopause. 2001; 8(1): 70‑5. https://dx.doi.org/10.1097/ 00042192‑200101000‑00012.
31. Mascarenhas C., Lambe M., Bellocco R., Bergfeldt K., Riman T., Persson I., Weiderpass E. Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival. Int. J. Cancer. 2006; 119(12): 2907‑15. https://dx.doi.org/10.1002/ijc.22218.
32. Power L., Lefas G., Lambert P., Kim D., Evaniuk D., Lotocki R. et al. Hormone use after nonserous epithelial ovarian cancer: overall and disease‑free survival. Obstet. Gynecol. 2016; 127(5): 837‑47. https://dx.doi.org/10.1097/ AOG.0000000000001396.
33. Li D., Ding C.-Y., Qiu L.-H. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta‑analysis. Gynecol. Oncol. 2015; 139(2): 355‑62. https://dx.doi.org/10.1016/ j.ygyno.2015.07.109.
34. Zhang Y.L., Chen J.H., Lu W., Li Bl.L., Zhu Q.Y., Wan X.P. Efficacy of postoperative hormone replacement therapy on prognosis of patients with serous ovarian carcinoma. Chin. Med. J. (Engl). 2016; 129(11): 1316‑21. https://dx.doi.org/10.4103/0366‑6999.182835.
35. Wentzensen N., Trabert B. Hormone therapy: short‑term relief, long‑term consequences. Lancet. 2015; 385(9980): 1806‑8. https://dx.doi.org/10.1016/ S0140‑6736(14)62458‑2.
36. Rousset-Jablonski C., Selle F., Adda-Herzog E., Planchamp F., Selleret L., Pomel C. et al. Fertility preservation, contraception and menopause hormone therapy in women treated for rare ovarian tumours: guidelines from the French national network dedicated to rare gynaecological cancers. Eur. J. Cancer. 2019; 116: 35‑44. https://dx.doi.org/10.1016/j.ejca.2019.04.018.
37. Gershenson D.M., Bodurka D.C., Coleman R.L., Lu K.H., Malpica A., Sun C.C. Hormonal maintenance therapy for women with low‑grade serous cancer of the ovary or peritoneum. J. Clin. Oncol. 2017; 35(10): 1103‑11. https://dx.doi.org/10.1200/JCO.2016.71.0632.
Received 27.12.2022
Accepted 04.04.2023
About the Authors
Nataliya А. Babaeva, Dr. Sci. Med., oncologist, Leading Researcher at the Instititute of Gynecological Oncology and Mammology, Academician V.I. Kulakov National Medical Research Center for Obsterics, Gynecology and Perinatology, Ministry of Health of Russia, +7(903)738-38-78, natbabaeva@yandex.ru,https://orcid.org/0000-0002-4654-9512117997, 117997, Russia, Moscow, Ac. Oparina str., 4.
Svetlana V. Yureneva, Dr. Sci. Med., obstetrician-gynecologist, oncologist, Deputy Director for Science of the Instititute of Gynecological Oncology and Mammology, Academician V.I. Kulakov National Medical Research Center for Obsterics, Gynecology and Perinatology, Ministry of Health of Russia, syureneva@gmail.com, https://orcid.org/0000-0003-2864-066X, 117997, Russia, Moscow, Ac. Oparina str., 4.
Olga I. Aleshikova, Ph.D., oncologist, Senior Researcher at the Instititute of Gynecological Oncology and Mammology, Academician V.I. Kulakov National Medical Research Center for Obsterics, Gynecology and Perinatology, Ministry of Health of Russia, olga.aleshikova@gmail.com http://orcid.org/0000-0002-2957-3940,
117997, Russia, Moscow, Ac. Oparina str., 4.
Oksana V. Yakushevskaya, Ph.D., obstetrician-gynecologist, oncologist, Researcher at the Department of Gynecological Endocrinology, Academician V.I. Kulakov National Medical Research Center for Obsterics, Gynecology and Perinatology, Ministry of Health of Russia, ykushox83@mail.ru, https://orcid.org/0002-7430-1207,
117997, Russia, Moscow, Ac. Oparina str., 4.
Levon A. Ashrafyan, Academician of the RAS, Professor, Dr. Sci. Med., Director of the Instititute of Gynecological Oncology and Mammology, Academician V.I. Kulakov National Medical Research Center for Obsterics, Gynecology and Perinatology, Ministry of Health of Russia, levaa2004@yahoo.com, https://orcid.org/0000-0001-6396-4948, 117997, Russia, Moscow, Ac. Oparina str., 4.
Corresponding autor: Nayaliya A. Babaeva, natbabaeva@yandex.ru
Similar Articles
